All lobbying filings

PERSONALIZED MEDICINE COALITION

PERSONALIZED MEDICINE COALITION filed a Q2 amendment for PERSONALIZED MEDICINE COALITION on March 5, 2026.

Lobbying for PERSONALIZED MEDICINE COALITION · Health care

All filings by PERSONALIZED MEDICINE COALITION · Everything PERSONALIZED MEDICINE COALITION has reported

Filing · LD-2 quarterly report Q2 amendment

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Mar 5, 2026

Expenses

$46,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 1

CYNTHIA BENS

Previously held: Staff, Representative Paul E. Kanjorski

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Congressional Personalized Medicine Caucus S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act House Energy and Commerce Committee Privacy Working Group Request for Information CMS Implementation of Medicare Drug Price Negotiation Program/ Medicare Drug Price Negotiation Program; Draft Guidance for the Medicare Drug Price Negotiation Program: Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2028 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026, 2027, and 2028 Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2026 Rates; Requirements for Quality Programs; and Other Policy Changes (CMS-1833-P) Office of Science and Technology Policy Request for Information on the Development of an Artificial Intelligence (AI) Action Plan Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations [FDA-2024-D-4488] Considerations for the Use of Artificial Intelligence to Support Regulatory Decision Making for Drug and Biological Products [FDA-2024-D-4689] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community

Budget/Appropriations

FY 2026 Food and Drug Administration Budget Priorities for CDER, CBER and CDRH FY 2026 National Institutes of Health Budget Priorities

Bills named in this filing 4

S. 832
EPIC Act of 2025
H.R. 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
H.R. 946
ORPHAN Cures Act
H.R. 1672
Maintaining Investments in New Innovation Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.